Exome Asset Management
Latest statistics and disclosures from Exome Asset Management's latest quarterly 13F-HR filing:
- Top 5 stock holdings are LLY, RDY, BGNE, CI, ALPN, and represent 25.52% of Exome Asset Management's stock portfolio.
- Added to shares of these 10 stocks: BGNE, RNA, CRBP, CNTA, AVTE, MOR, KRYS, TVTX, INZY, ELEV.
- Started 28 new stock positions in CNTA, ELVN, OLMA, AVTE, ADAG, TERN, IMAB, VTYX, EXAS, GH.
- Reduced shares in these 10 stocks: , INBX, GPCR, RCKT, LEGN, ALPN, BHVN, LNTH, , CLDX.
- Sold out of its positions in APLS, CABA, CPRX, EYPT, Gracell Biotechnologies, IGMS, ImmunoGen, INBX, KNTE, LNTH.
- Exome Asset Management was a net buyer of stock by $7.3M.
- Exome Asset Management has $117M in assets under management (AUM), dropping by 15.47%.
- Central Index Key (CIK): 0002011932
Tip: Access up to 7 years of quarterly data
Positions held by Exome Asset Management consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Exome Asset Management
Exome Asset Management holds 53 positions in its portfolio as reported in the March 2024 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Eli Lilly & Co. (LLY) | 6.5 | $7.5M | 9.7k | 777.96 |
|
|
| Dr Reddys Labs Adr (RDY) | 5.4 | $6.3M | -4% | 86k | 73.35 |
|
| Beigene Sponsored Adr (BGNE) | 4.9 | $5.8M | +187% | 37k | 156.39 |
|
| Cigna Corp (CI) | 4.8 | $5.6M | 15k | 363.19 |
|
|
| Alpine Immune Sciences (ALPN) | 4.0 | $4.6M | -32% | 117k | 39.64 |
|
| Tg Therapeutics (TGTX) | 3.0 | $3.5M | +13% | 230k | 15.21 |
|
| Avidity Biosciences Ord (RNA) | 3.0 | $3.4M | NEW | 135k | 25.52 |
|
| Corbus Pharmaceuticals Hldgs Com New (CRBP) | 3.0 | $3.4M | NEW | 88k | 39.24 |
|
| Dex (DXCM) | 2.9 | $3.4M | 25k | 138.70 |
|
|
| Centessa Pharmaceuticals Sponsored Ads (CNTA) | 2.7 | $3.1M | NEW | 275k | 11.30 |
|
| Celldex Therapeutics Com New (CLDX) | 2.6 | $3.0M | -36% | 71k | 41.97 |
|
| Geron Corporation (GERN) | 2.5 | $2.9M | +45% | 887k | 3.30 |
|
| Aerovate Therapeutics (AVTE) | 2.5 | $2.9M | NEW | 99k | 29.57 |
|
| Morphosys Sponsored Ads (MOR) | 2.4 | $2.8M | NEW | 155k | 18.14 |
|
| Travere Therapeutics (TVTX) | 2.4 | $2.8M | +331% | 363k | 7.71 |
|
| Krystal Biotech (KRYS) | 2.2 | $2.6M | NEW | 15k | 177.93 |
|
| Intuitive Surgical Com New (ISRG) | 2.2 | $2.5M | 6.4k | 399.09 |
|
|
| Tarsus Pharmaceuticals (TARS) | 2.1 | $2.4M | -21% | 66k | 36.35 |
|
| Madrigal Pharmaceuticals (MDGL) | 1.8 | $2.1M | -40% | 7.9k | 267.04 |
|
| Inozyme Pharma (INZY) | 1.8 | $2.1M | NEW | 273k | 7.66 |
|
| Rhythm Pharmaceuticals (RYTM) | 1.7 | $2.0M | -36% | 46k | 43.33 |
|
| Insmed Com Par $.01 (INSM) | 1.7 | $1.9M | +16% | 72k | 27.13 |
|
| Elevation Oncology (ELEV) | 1.6 | $1.9M | NEW | 369k | 5.13 |
|
| EXACT Sciences Corporation (EXAS) | 1.6 | $1.8M | NEW | 27k | 69.06 |
|
| Cytokinetics Com New (CYTK) | 1.6 | $1.8M | -25% | 26k | 70.11 |
|
| Regenxbio Inc equity us cm (RGNX) | 1.5 | $1.8M | NEW | 85k | 21.07 |
|
| Biogen Idec (BIIB) | 1.5 | $1.8M | 8.2k | 215.63 |
|
|
| Ocular Therapeutix (OCUL) | 1.5 | $1.8M | NEW | 194k | 9.10 |
|
| Agios Pharmaceuticals (AGIO) | 1.5 | $1.8M | NEW | 60k | 29.24 |
|
| Natera (NTRA) | 1.5 | $1.7M | 19k | 91.46 |
|
|
| Penumbra (PEN) | 1.4 | $1.6M | -14% | 7.4k | 223.18 |
|
| Guardant Health (GH) | 1.4 | $1.6M | NEW | 79k | 20.63 |
|
| Olema Pharmaceuticals (OLMA) | 1.4 | $1.6M | NEW | 143k | 11.32 |
|
| Arrowhead Pharmaceuticals (ARWR) | 1.4 | $1.6M | NEW | 56k | 28.60 |
|
| Bridgebio Pharma (BBIO) | 1.3 | $1.5M | -25% | 49k | 30.92 |
|
| Terns Pharmaceuticals (TERN) | 1.3 | $1.5M | NEW | 228k | 6.56 |
|
| Marinus Pharmaceuticals Com New (MRNS) | 1.3 | $1.5M | NEW | 163k | 9.04 |
|
| Inari Medical Ord (NARI) | 1.2 | $1.4M | NEW | 30k | 47.98 |
|
| Quanterix Ord (QTRX) | 1.2 | $1.4M | NEW | 60k | 23.56 |
|
| Intra Cellular Therapies (ITCI) | 1.2 | $1.4M | -28% | 20k | 69.20 |
|
| Shockwave Med (SWAV) | 1.1 | $1.3M | 4.0k | 325.63 |
|
|
| Vyne Therapeutics (VYNE) | 1.1 | $1.3M | +251% | 415k | 3.07 |
|
| Regulus Therapeutics (RGLS) | 1.0 | $1.2M | +125% | 403k | 2.88 |
|
| Q32 Bio | 0.9 | $1.1M | NEW | 65k | 17.04 |
|
| Zai Lab Adr (ZLAB) | 0.9 | $1.0M | NEW | 65k | 16.02 |
|
| Enliven Therapeutics (ELVN) | 0.9 | $1.0M | NEW | 58k | 17.59 |
|
| Ventyx Biosciences (VTYX) | 0.8 | $902k | NEW | 164k | 5.50 |
|
| Ultragenyx Pharmaceutical (RARE) | 0.7 | $831k | NEW | 18k | 46.69 |
|
| I Mab Sponsored Ads (IMAB) | 0.5 | $606k | NEW | 326k | 1.86 |
|
| Adagene Ads (ADAG) | 0.4 | $435k | NEW | 155k | 2.80 |
|
| Sagimet Biosciences Com Ser A (SGMT) | 0.3 | $330k | NEW | 61k | 5.42 |
|
| Pacific Biosciences of California (PACB) | 0.2 | $282k | 75k | 3.75 |
|
|
| Avrobio Ord (AVRO) | 0.1 | $78k | NEW | 61k | 1.28 |
|
Past Filings by Exome Asset Management
SEC 13F filings are viewable for Exome Asset Management going back to 2023
- Exome Asset Management 2024 Q1 filed May 15, 2024
- Exome Asset Management 2023 Q4 filed Feb. 15, 2024